Aligos Therapeutics (ALGS) Liabilities and Shareholders Equity (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $66.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 50.76% year-over-year to $66.3 million; the trailing twelve-month figure through Jun 2026 stood at $329.2 million (down 25.85% YoY), and the FY2025 full-year result was $88.5 million, up 26.31% from the prior year.
• Liabilities and Shareholders Equity advanced to $66.3 million in Q2 2026 per ALGS's latest filing, from $64.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $210.5 million in Q1 2022 and bottomed at $64.6 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $121.0 million across 5 years, with a median of $115.8 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity grew 26.31% in 2025, then tumbled 57.16% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $146.7 million in 2022, then gained by 3.3% to $151.5 million in 2023, then plunged by 53.74% to $70.1 million in 2024, then advanced by 26.31% to $88.5 million in 2025, then declined by 25.08% to $66.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $66.3 million, $64.6 million, and $88.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.